Vista and Medtronic agree to part company:
This article was originally published in Clinica
Vista Medical Technologies and Medtronic have terminated the three agreements between them that related to selling Vista's Series 8000 visualisation and information system for cardiac procedures. Vista says the exclusive agreements were cancelled because the endoscopic bypass surgery market has failed to develop as the Carlsbad, California-based company had predicted. However, it says that it is negotiating with another "international cardiac products company" for worldwide exclusive distribution of the visualisation system.
You may also be interested in...
The European Commission has granted a marketing authorization for UCB and Amgen’s bone-building MAb, romosozumab, and first launches are expected in the first half of 2020; patient groups suggest that the prevention and treatment of fragility fractures has not attracted the attention it deserves.
The International Generic and Biosimilar Medicines Association has urged the World Intellectual Property Organization to withdraw its support for a global database of pharmaceutical patent information. The Pat-INFORMED database – which is comprised of intellectual-property information provided by originators – contains unverified data and lacks appropriate safeguards, the IGBA contends.
Reforms to the US 180-day exclusivity incentive included in the Blocking Act that is part of the Lower Health Care Costs Act could cost the US healthcare system approximately $1.7bn, the AAM has warned.